Effects of acetyl-dl-leucine in patients with cerebellar ataxia: A case series

Journal of Neurology

Volumn 260, Issue 10, 2013, Pages 2556-2561

  Strupp, Michael ^a   Teufel, Julian ^a   Habs, Maximilian ^a   Feuerecker, Regina ^a   Muth, Carolin ^a   Van De Warrenburg, Bart P ^b   Klopstock, Thomas ^a,c   Feil, Katharina ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RADBOUD UNIVERSITY   (Netherlands)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Acetyl dl leucine; Ataxia; Cerebellar ataxia; Cerebellum; Pharmacotherapy

Indexed keywords

N ACETYLLEUCINE ETHANOLAMINE;

ADCA GENE; ADOLESCENT; ADULT; AGED; AOA GENE; ARTICLE; ATAXIN 1 GENE; ATAXIN 2 GENE; CEREBELLAR ATAXIA; CLINICAL ARTICLE; FEMALE; GAIT; GENE; HUMAN; MALE; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; SAOA GENE; SPEECH;

ADOLESCENT; ADULT; AGED; CEREBELLAR ATAXIA; DISABILITY EVALUATION; FEMALE; HUMANS; LEUCINE; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886086913     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7016-x     Document Type: Article

References (24)

1. Manto M, Marmolino D (2009) Cerebellar ataxias. Curr Opin Neurol 22:419-429
2. Strupp M, Schuler O, Krafczyk S et al (2003) Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 61:165-170
3. Strupp M, Kalla R, Claassen J et al (2011) A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77:269-275
4. Schniepp R, Wuehr M, Neuhaeusser M et al (2012) 4-Aminopyridine and cerebellar gait: a retrospective case series. J Neurol 259:2491-2493
5. Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L (2009) Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 73:1823-1830
6. Klockgether T (2005) Ataxias. Diagnostic procedure and treatment. Nervenarzt 76:1275-1283
7. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL (1995) The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92:11746-11750
8. Ferber-Viart C, Dubreuil C, Vidal PP (2009) Effects of acetyl-dl-leucine in vestibular patients: a clinical study following neurotomy and labyrinthectomy. Audiol neuro-otol 14:17-25
9. Lacour M (1995) Influence d'un traitement pharmacologique à l'acétyl-dl-leucine dans la compensation des déficits vestibulaires chez le chat. Dissertation/report. Rapport de fin d'études établit pour les Laboratoires Pierre Fabre. Pierre Fabre Médicaments, Castres
10. Léger A, Schnerb A, Lejeune D, Glisse J-C, Vieillefond H (1986) Effet de l'acétyl-dl-leucine sur les caractéristiques du réflexe vestibulooculaire per- et post-rotatoire. Médecine des armées 13:269-273
11. Neuzil E, Ravaine S, Cousse H (2002) La N-acétyl-dl-leucine, médicament symptomatique de vertigineux. Bulletin de la société de pharmacie de Bordeaux 141:15-38
12. Vibert N, Vidal PP (2001) In vitro effects of acetyl-dl-leucine (Tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur J Neurosci 13:735-748
13. Mori M, Adachi Y, Mori N et al (2002) Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. J Neurol Sci 195:149-152
14. Highstein SM, Holstein GR (2006) The anatomy of the vestibular nuclei. Prog Brain Res 151:157-203
15. Subramony SH (2007) SARA-a new clinical scale for the assessment and rating of ataxia. Nat Clin Pract Neurol 3:136-137
16. Weyer A, Abele M, Schmitz-Hubsch T et al (2007) Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov Disord 22:1633-1637
17. Schmitz-Hubsch T, du Montcel ST, Baliko L et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717-1720
18. Schmitz-Hubsch T, Giunti P, Stephenson DA et al (2008) SCA functional index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71:486-492
19. Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol group. Ann Med 33:337-343
20. Zesiewicz TA, Greenstein PE, Sullivan KL et al (2012) A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 78:545-550
21. Ristori G, Romano S, Visconti A et al (2010) Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74:839-845
22. Boesch S, Sturm B, Hering S et al (2008) Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord 23:1940-1944
23. Suh BC, Hille B (2008) PIP2 is a necessary cofactor for ion channel function: how and why? Annual Rev Biophys 37:175-195
24. Witter L, De Zeeuw CI, Ruigrok TJ, Hoebeek FE (2011) The cerebellar nuclei take center stage. Cerebellum 10:633-636